Overview

NeoStem: NASDAQ:NBS

• Integrated biotechnology Company with as strong pipeline based on multiple platform technologies that include Phase 2 and 3 assets and a revenue generating contract development and manufacturing business
• Five (5) issued patents, seventeen (17) matter and method patterns and fourty-four (44) pending patents
• Exclusive rights to twenty-three (23) issued and nine (9) pending patents
  in-licensed from the University of Louisville to the world-wide patent rights for the isolation, purification and therapeutic use of very small embryo-like (VSEL) stem cells
• Headquarters in New York
• GMP compliant facilities in Allendale-NJ, Mountain View-CA and 
  Irvine-CA
• 168 employees as of September 30, 2014
• Executed six sector specific acquisitions
• NASDAQ CM: NBS
• Market Cap $144 Mill
• $32.8 Mill in cash and marketable securities as of September 30, 2014

https://stockwatchindex.com/neostem/